Abstract
Given the broad treatment options, risk stratification of pulmonary embolism is a highly desirable component of management. The ideal tool identifies patients at risk of death from the original or recurrent pulmonary embolism. Using all-cause death in the first 30-days after pulmonary embolism diagnosis as a surrogate, clinical parameters, biomarkers, and radiologic evidence of right ventricular dysfunction and strain are predictive. However, no study has demonstrated improved mortality rates after implementation of a risk stratification strategy to guide treatment. Further research should use better methodology to study prognosis and test new management strategies in patients at high risk for death.
| Original language | English |
|---|---|
| Pages (from-to) | 437-448 |
| Number of pages | 12 |
| Journal | Critical Care Clinics |
| Volume | 36 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2020 |
| Externally published | Yes |
Keywords
- Biomarkers
- Clinical assessment
- Mortality
- Prognosis
- Pulmonary embolism
- Risk stratification
Fingerprint
Dive into the research topics of 'Risk Stratification of Pulmonary Embolism'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver